Clenbuterol
Based on 6 publication(s) in Google Scholar
Clenbuterol (NAB-365) is a β2-adrenergic receptor agonist with an EC50 of 31.9 nM. Clenbuterol is a very potent inhibitor of the lipopolysaccharide (LPS)-induced release of TNF-α and IL-1β. Clenbuterol can inhibit the inflammatory process. Clenbuterol is a bronchodilator.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 37148-27-9
- Formel: C12H18Cl2N2O
- Molecular Weight:277.19
-
Speicherung:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Clenbuterol
MoreAlle Adrenergic Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Sf9 | IC50 |
1.3 μM
Compound: (rac)-2
|
Displacement of [3H]CGP1217 from human recombinant adrenergic beta2 receptor transfected in insect Sf9 cells by scintillation counting
Displacement of [3H]CGP1217 from human recombinant adrenergic beta2 receptor transfected in insect Sf9 cells by scintillation counting
|
[PMID: 19245211] |
Clenbuterol (NAB-365) is a selective β2-adrenergic agonist (β2/β1 ratio = 4.0). Clenbuterol is a very potent inhibitor of the lipopolysaccharide (LPS)-induced release of TNF-α and IL-1β. Clenbuterol can inhibit the inflammatory process[2].
Clenbuterol (10-200 μM; for 24 or 48 hours) decreases the viability of C2C12 myoblasts. Clenbuterol (100 μM) significantly decreases DNA synthesis. Clenbuterol (100 μM; for 12 h) increases the proportion of cells in G0/G1 phase. Clenbuterol treatment delays cell cycle progression. Clenbuterol (100 μM) induces cell cycle arrest, but not apoptosis, in C2C12 myoblasts[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:C2C12 cells.
-
Concentration:0, 10, 100, and 200 µM.
-
Incubation Time:24 and 48 hours.
-
Result:Treatment reduced viability of C2C12 cells for 24 and 48 h.
Clenbuterol is a bronchodilator. Clenbuterol (90 μg) is administered intratracheally to five horses. Peak serum concentrations of ~230 pg/mL are detected 10 min after administration, dropping to ~50 pg/mL within 30 min and declining much more slowly thereafter. Intratracheal administration of clenbuterol shortly before race time can be detected with this serum test[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Mecp2−/y and female Mecp2−/+ mice[4]
-
Dosage:5 or 0.1 mg/kg.
-
Administration:Injected i.p.; daily for 5 d, followed by a 2-d off period, repeated weekly
-
Result:Significantly improved the phenotype during the second but not first day of testing, implying a modest effect on motor coordination in Mecp2-null mice.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 37148-27-9
-
Appearance Solid
-
Molecular Weight 277.19
-
Formel C12H18Cl2N2O
-
Color White to off-white
-
SMILES
CC(C)(NCC(C1=CC(Cl)=C(C(Cl)=C1)N)O)C
-
Synonyms
NAB-365
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
DeSiphering receptor core-induced and ligand-dependent conformational changes in arrestin via genetic encoded trimethylsilyl 1H-NMR probe. [Abstract]2020 Sep 25;11(1):4857. PMID: 32978402 -
Adv Sci (Weinh)
Pharmacological Microglial Inhibition Remodels the Scar Microenvironment to Support Reticulospinal Circuit Reconstruction After Spinal Cord Injury. [Abstract]2025 Oct 17:e03966. PMID: 41103249 -
Adv Sci (Weinh)
2021 Dec;8(24):e2100808. PMID: 34719888 -
Cell Rep
2025 Sep 23;44(10):116337. PMID: 40991929 -
Toxicol In Vitro
Development of 3D-QSAR models for predicting the activities of chemicals to stimulate muscle growth via β2-adrenoceptor. [Abstract]2021 Dec:77:105251. PMID: 34601065 -
Reinheit & Dokumentation
Verweise
[1]. Gilad Barnea, et al. The genetic design of signaling cascades to record receptor activation. Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):64-9. [Content Brief]
[2]. Olga Witkowska-Piłaszewicz, et al. The Effect of the Clenbuterol-β2-Adrenergic Receptor Agonist on the Peripheral Blood Mononuclear Cells Proliferation, Phenotype, Functions, and Reactive Oxygen Species Production in Race Horses In Vitro. Cells. 2021 Apr 17;10(4):936. [Content Brief]
[3]. Min Chen, et al. Clenbuterol Induces Cell Cycle Arrest in C2C12 Myoblasts by Delaying p27 Degradation through β-arrestin 2 Signaling. Int J Biol Sci. 2017 Oct 17;13(10):1341-1350. [Content Brief]
[4]. Nikolaos Mellios, et al. β2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome. Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9947-52. [Content Brief]
[5]. A F Lehner, et al. Clenbuterol in the horse: confirmation and quantitation of serum clenbuterol by LC-MS-MS after oral and intratracheal administration. J Anal Toxicol. May-Jun 2001;25(4):280-7. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)